Cellid Ltd.

Cellid Co., Ltd. develops immunotherapeutic vaccines for oncology and infectious diseases. Its pipeline—BVAC‑C, BVAC‑B, BVAC‑P, BVAC‑M, and personalized BVAC‑Neo—targets HPV‑related, HER‑2, PSA, and melanoma cancers, positioning the company in emerging precision‑medicine markets.

Headquarters: South Korea (KOR)

Cellid Ltd. Logo
Company Profile
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
299660 Cellid Ltd.
Cap: 77.9B
EQUITY KOE KRW KR7299660001 Active
📈
Home Login